Leflunomide Tablet
Product Images NDC 72162-2409

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 72162-2409). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Cfa52b95 F6ee 4a2c A320 E190f716d33b 01)

Chemical structure diagram of leflunomide, illustrating its molecular framework with labeled functional groups including a trifluoromethyl-substituted phenyl ring and an isoxazole ring with methyl and cyano groups.*

FDA Label Image

. (Cfa52b95 F6ee 4a2c A320 E190f716d33b 02)

Chemical structure of teriflunomide, the active metabolite of leflunomide, showing its molecular configuration including trifluoromethyl group and cyanide functional group.*

FDA Label Image

Image (Cfa52b95 F6ee 4a2c A320 E190f716d33b 03)

A bar chart titled '% ACR 20 Responder at Endpoint' comparing the response percentages of leflunomide, methotrexate, placebo, and sulfasalazine across three clinical trials of varying durations (12 months, 6 months, 12 months). The vertical axis shows percentage response, with leflunomide and comparator drugs displayed for each trial.*

FDA Label Image

Image (Cfa52b95 F6ee 4a2c A320 E190f716d33b 04)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders on the y-axis against months on the x-axis (ranging from 0 to 12 months). It compares three groups labeled as PL (placebo), MTX (methotrexate), and LEF (leflunomide) with different markers: circle for PL, square for MTX, and triangle for LEF. The graph tracks response rates over time up to 12 months. A footnote indicates '*Last Observation Carried Forward.'*

FDA Label Image

. (Cfa52b95 F6ee 4a2c A320 E190f716d33b 05)

A bar chart titled 'Change in Sharp Score' comparing progression values across three clinical trials over 6 to 12 months. The chart displays bars for Leflunomide (L), Methotrexate (M), Sulfasalazine (S), and Placebo (P) in different trials, showing various numeric scores associated with each treatment group.*

FDA Label Image

. (Cfa52b95 F6ee 4a2c A320 E190f716d33b 06)

A bar chart titled "Change in Functional Ability Measure*" showing improvement scores from three clinical trials at different time points (6 or 12 months). The chart compares the functional ability changes for leflunomide (L), methotrexate (M), placebo (P), and sulfasalazine (S) using the HAQ Disability Index. Bars indicate the degree of improvement, with leflunomide generally showing more negative values (greater improvement) compared to placebo and other comparators across trials.*

FDA Label Image

4b95cee-6630-482c-93a4-2a489f7c0c03 (Cfa52b95 F6ee 4a2c A320 E190f716d33b 07)

FDA Label Image

Label (Lbl721622409)

Label for Leflunomide Tablets, USP 10 mg oral tablets. The label indicates a package size of 30 tablets. It includes storage instructions to keep at 25°C with permitted excursions, protection from light, and a warning to keep out of children's reach. The labeler is Bryant Ranch Prepack, with Heritage Pharma Labs Inc. noted as the manufacturer. The product NDC is 72162-2409-3.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.